Abstract 1970: miRNA differential profiling between fibroblasts originated from breast cancer and normal adjacent tissue from benign disease

ABSTRACTIn the United States, 1 in 8 women will be diagnosed with breast cancer in her lifetime. Along with genetics, the environment contributes to disease development, but what these exact environmental factors are remains unknown. We have previously shown that breast tissue is not sterile but contains a diverse population of bacteria. We thus believe that the host's local microbiome could be modulating the risk of breast cancer development. Using 16S rRNA amplicon sequencing, we show that bacterial profiles differ between normal adjacent tissue from women with breast cancer and tissue from healthy controls. Women with breast cancer had higher relative abundances ofBacillus,EnterobacteriaceaeandStaphylococcus.Escherichia coli(a member of theEnterobacteriaceaefamily) andStaphylococcus epidermidis, isolated from breast cancer patients, were shown to induce DNA double-stranded breaks in HeLa cells using the histone-2AX (H2AX) phosphorylation (γ-H2AX) assay. We also found that microbial profiles are similar between normal adjacent tissue and tissue sampled directly from the tumor. This study raises important questions as to what role the breast microbiome plays in disease development or progression and how we can manipulate this for possible therapeutics or prevention.IMPORTANCEThis study shows that different bacterial profiles in breast tissue exist between healthy women and those with breast cancer. Higher relative abundances of bacteria that had the ability to cause DNA damagein vitrowere detected in breast cancer patients, as was a decrease in some lactic acid bacteria, known for their beneficial health effects, including anticarcinogenic properties. This study raises important questions as to the role of the mammary microbiome in modulating the risk of breast cancer development.

Download Full-text

P11 Loss of retinoic acid receptor β expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer

European Journal of Cancer ◽

10.1016/s0959-8049(97)89229-5 ◽

1998 ◽

Vol 34 ◽

pp. S17 ◽

Cited By ~ 3

Author(s):

M. Widschwendter ◽

J. Berger ◽

G. Daxenbichler ◽

A. Widschwendter ◽

A.G. Zeimet ◽

...

Keyword(s):

Breast Cancer ◽

Retinoic Acid ◽

Breast Tissue ◽

Normal Breast Tissue ◽

Retinoic Acid Receptor ◽

Normal Breast ◽

Adjacent Tissue ◽

Normal Adjacent Tissue ◽

Acid Receptor

Download Full-text

Bilateral Florid Papillomatosis of the Nipple: An Unusual Indicator for Metachronous Breast Cancer Development—A Case Report

Case Reports in Oncological Medicine ◽

10.1155/2014/432609 ◽

2014 ◽

Vol 2014 ◽

pp. 1-3 ◽

Cited By ~ 1

Author(s):

Walid Sasi ◽

Dibyesh Banerjee ◽

Kefah Mokbel ◽

Anup K. Sharma

Keyword(s):

Breast Cancer ◽

Case Report ◽

Literature Review ◽

Papillary Carcinoma ◽

Rare Case ◽

Benign Disease ◽

Cancer Development ◽

Breast Cancer Development ◽

Histopathological Features ◽

Metachronous Breast Cancer

Adenoma or florid papillomatosis of the nipple (FPN) is a rare benign disease which has histopathological features similar to those of a mammary papillary carcinoma. Here, we report a rare case of bilateral florid papillomatosis of the nipple and breast cancer, with a literature review.

Download Full-text

Abstract 4624: Differentiation of female donors classified as “normal”, with benign disease and with breast cancer based on blood RNA signature

10.1158/1538-7445.am10-4624 ◽

2010 ◽

Author(s):

Richard I. Somiari ◽

Stephen Russell ◽

Seema Bharathan ◽

James Lyons-Weiler ◽

Stella A. Somiari

Keyword(s):

Breast Cancer ◽

Benign Disease ◽

Rna Signature

Download Full-text

Clinical characteristics of breast ductal carcinoma in situ with microinvasion: a narrative review

Journal of International Medical Research ◽

10.1177/0300060520969304 ◽

2020 ◽

Vol 48 (11) ◽

pp. 030006052096930

Author(s):

Jie Zheng ◽

Jingjing Yu ◽

Tao Zhou

Keyword(s):

Breast Cancer ◽

Ductal Carcinoma In Situ ◽

Carcinoma In Situ ◽

Clinical Characteristics ◽

Ductal Carcinoma ◽

Narrative Review ◽

Maximum Diameter ◽

Adjacent Tissue ◽

Prognostic Features

Ductal carcinoma in situ (DCIS) with microinvasion (DCIS-MI) is defined as the extension of cancer cells beyond the basement membrane into adjacent tissue with no focus larger than 1 mm or a maximum diameter of less than 1 mm for multiple invasive foci. DCIS-MI constitutes approximately 1% of all breast cancer cases and 5% to 10% of cases of DCIS. The current literature is controversial concerning the clinical prognostic features and management of DCIS-MI. This narrative review described recently reported literature regarding the characteristics, diagnosis, treatment, and prognosis of DCIS-MI.

Download Full-text

Angle between 1 and 4 min gives the most significant difference in time–intensity curves between benign disease and breast cancer: analysis of dynamic magnetic resonance imaging in 103 patients with breast lesions

Clinical Imaging ◽

10.1016/j.clinimag.2008.12.001 ◽

2009 ◽

Vol 33 (5) ◽

pp. 335-342 ◽

Cited By ~ 1

Author(s):

Masayasu Hara ◽

Takeshi Watanabe ◽

Akie Okumura ◽

Kazuko Kato ◽

Noriaki Mohri ◽

...

Keyword(s):

Breast Cancer ◽

Magnetic Resonance Imaging ◽

Magnetic Resonance ◽

Dynamic Magnetic Resonance Imaging ◽

Benign Disease ◽

Breast Lesions ◽

Resonance Imaging ◽

Dynamic Magnetic Resonance ◽

Significant Difference

Download Full-text

Clinical experience with the new manual and automated large core biopsy systems based on a rotational cutting on a helix

Journal of Clinical Oncology ◽

10.1200/jco.2007.25.18_suppl.1550 ◽

2007 ◽

Vol 25 (18_suppl) ◽

pp. 1550-1550

Author(s):

J. P. Janssens ◽

L. Rotenberg ◽

M. Sentis ◽

R. Schultz-Wendtland

Keyword(s):

Breast Cancer ◽

Patient Satisfaction ◽

Clinical Practice ◽

Tumor Cell ◽

Core Biopsy ◽

Average Length ◽

Benign Disease ◽

Large Core ◽

Large Core Biopsy

1550 Background: Survival from breast cancer has increased significantly in recent years mainly as a result from better imaging techniques, earlier detection and improved tissue sampling. Newer technologies should improve existing biopsies because major drawbacks, including tumor cell displacement, preclude women and physicians to biopsy suspect lesions. A new large core biopsy device with a direct frontal approach, lesser side effects, less sampling needs, lower costs and improved yields has been evaluated in clinical practice. Methods: The results of 70 subsequent transdermal biopsies with rotational cutting on a helix are evaluated with regard to quality of the sample, patient satisfaction and completeness of diagnosis. The patients with a suspect lesion in the breast are selected in an oncological practice. Malignancy was verified by subsequent excision of the lesion. Attention was given to tumor cell displacement. Benign disease was verified by the subsequent clinical course. Results: In 69 patients at least one high quality sample with an average length of 1.8 cm and 0.3 cm diameter could be obtained. One patient refused the procedure. The average number of biopsy cores needed to obtain a reliable diagnosis was 1.5 (mininum 1 - maximum 5). No complication was noted with regard to pain, hemorrhagy, infection or other wound problems. 64 patients quoted the procedure as relative pain free. In 69 patients the diagnosis was complete with regard to the diagnosis of malignancy or benign disease. No destruction, biopsy artefacts or cell displacement was noted on histopathology. In all diagnoses with malignancy the grade of the tumor could be reliably given as well as steroid receptor content and HER2 immunohistochemistry. FISH-HER2 tests were possible in all HER2 positive tumors. Automated biopsies with vacuumassistance had slightly larger samples compared to the manual technique. Conclusions: The new large core biopsy technique with a rotational cutting on a helix performs well in clinical practice. All developmental goals with regard to quality of sample, patient satisfaction and cost price per biopsy have been met. Large core biopsies are now available for a larger population of women at risk for breast cancer with less risk of complication. No significant financial relationships to disclose.

Download Full-text

Methylation-specific high-resolution melting analysis (MS-HRM)-based DNA promoter profiling in paired FFPE bladder cancer samples.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.5_suppl.315 ◽

2012 ◽

Vol 30 (5_suppl) ◽

pp. 315-315

Author(s):

Wei Meng ◽

Arnab Chakravarti ◽

Tim Lautenschlaeger

Keyword(s):

Dna Methylation ◽

Bladder Cancer ◽

High Resolution ◽

Promoter Methylation ◽

High Resolution Melting ◽

Tissue Samples ◽

Adjacent Tissue ◽

Normal Adjacent Tissue ◽

Platinum Based Chemotherapy ◽

Cancer Tissues

315 Background: DNA methylation and histone modification are widely studied epigenetic events that can decrease gene expression levels. Promoter hypermethylation has been proposed as a potential diagnostic or prognostic biomarker in various cancers. We studied DNA promoter methylation of 5 cancer-associated genes (MRE11, APX1, ERCC1, RASSF1A and RASSF2A ) in paired FFPE bladder cancer tissues and normal adjacent tissue. The MRE11/Rad50/NBS1 complex serves as a single-strand DNA nuclease which participates in the repair of DNA double-strand breaks and replication errors. APX1 plays a key role in regulating H2O2 levels and H2O2 signaling. DNA repair machinery, ERCC1 protein levels in tumor tissue have been shown to predict response to platinum-based chemotherapy. RASSF1 is thought to be a tumor suppressor gene, while the function of RASSF2 is less well understood. Methods: 16 bladder cancer cases with available paraffin-embedded tumor and matched normal adjacent tissue specimens (32 tissue samples) were analyzed. DNA was extracted by Ambion RecoverAll Total Nucleic Acid Isolation kit. FFPE DNA bisulfite modification was performed using Zymo EZ DNA Methylation Kit. Methylation Specific-High Resolution Melting (MS-HRM) analysis was used to assess methylation status. MS-HRM monitors the melting behavior of PCR amplicons by using a DNA intercalating fluorescent dye. Results: MRE11 and APX1 promoters were not methylated in either cancer or normal adjacent samples. The ERCC1 gene was heavily methylated in 94% (30/32) of all cancer and wild type samples. RASSF1A and RASSF2A promoter methylation was significantly different between cancer and normal adjacent tissue. 50% (8/16) RASSF1A and 25% (4/16) RASSF2A had promoter methylation in cancer tissues, while only 6% (1/16) RASSF1A and 0% (0/16) RASSF2A had promoter methylation in normal adjacent tissues. 69% (11/16) of bladder cancer tissues were positive for RASSF1A or RASSF2A promotor methylation while only 1/16 normal adjacent tissue samples was positive for either promotor methylation. Conclusions: The results show that cancer and non-cancer tissue have different RASSF1A and RASSF2A promoter methylation patterns.

Download Full-text

Adherence rates to endocrine therapy among African American women with stage I-III, hormone receptor-positive breast cancer treated at Grady Memorial Hospital in Atlanta, Georgia.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e11582 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e11582-e11582

Author(s):

Megan Jean McKee ◽

Danny Nguyen ◽

Seham Al Haddad ◽

Elsa Paplomata ◽

Marjorie Adams Curry ◽

...

Keyword(s):

Breast Cancer ◽

African American ◽

African American Women ◽

Endocrine Therapy ◽

Metastatic Disease ◽

Breast Cancer Mortality ◽

Benign Disease ◽

Memorial Hospital ◽

Adherence Rate ◽

Caucasian Women

e11582 Background: Breast cancer mortality has historically been higher in African American (AA) women compared to Caucasian women. Controlling for tumor characteristics, biological markers and comorbidities does not account for the disparity. Previous studies have shown that AA women are more likely to have a high 21-gene recurrence score compared to Caucasian women. Another potential variable affecting treatment outcomes is adherence to adjuvant endocrine therapy (ET). We conducted a retrospective review of pharmacy records at Grady Memorial Hospital (GMH) to examine the non-adherence rate among predominantly AA patients (pts). Methods: Pharmacy database records were examined for pts filling prescriptions for tamoxifen, anastrozole, or letrozole at GMH in Atlanta, Georgia from 2004-2009. Baseline characteristics were obtained by chart review. Pts were excluded if they had metastatic disease, DCIS, less than 60 days of eligible prescription, were male, deceased during the study period, benign disease, or no documentation of breast cancer in the electronic medical record (EMR). Non-adherence was defined as those filling less than 80% of eligible days covered by her prescription. Results: 679 pts were identified who filled prescriptions for tamoxifen, anastrozole, or letrozole at Grady pharmacy from 2004-2009. Pts who were excluded had metastatic disease (152), DCIS (101), had less than 60 days of eligible prescription (65), had no documentation of breast cancer in the EMR (25), were male (6), deceased before 2009 (5), or had benign disease (9). Of the 316 pts eligible for the study, median age was 60 (26 to 94) at time of diagnosis, 86% were AA, and 39% were node positive. 167 pts filled prescriptions for tamoxifen, 95 for anastrozole, and 54 for letrozole. The non-adherence rate for tamoxifen was 50%, anastrozole 38%, and letrozole 48%. Overall non-adherence rate was 46%. Conclusions: The overall non-adherence rate to adjuvant ET among a predominately AA population seen in a county hospital was similar to previously reported rates. Non-adherence to ET in this underserved AA pt population does not fully account for disparate outcomes.

Download Full-text